Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
2020 · Breast Cancer Research and Treatment · 103 citations
https://doi.org/10.1007/s10549-020-06001-w
F
Fabrizio De Ponti
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
404
Papers
11.2K
Citations
55
h-index
204
i10-index
Fabrizio De Ponti is an academic researcher from University of Bologna. The author has contributed to research in topics: Gastrointestinal motility and disorders & Pharmacovigilance and Adverse Drug Reactions & Neuropeptides and Animal Physiology. The author has an h-index of 55, co-authored 344 publications.
ORCID: 0000-0002-0367-9595Papers by this author
worksCardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology
2011 · Internal and Emergency Medicine · 55 citations
https://doi.org/10.1007/s11739-011-0744-y
Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement
2003 · European Journal of Clinical Pharmacology · 46 citations
https://doi.org/10.1007/s00228-003-0692-1
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
2020 · Drug Safety · 42 citations
https://doi.org/10.1007/s40264-020-00975-8
Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection
2015 · Drug Safety · 36 citations
https://doi.org/10.1007/s40264-015-0288-6
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
2024 · Targeted Oncology · 32 citations
https://doi.org/10.1007/s11523-024-01058-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat